Information om | Engelska ordet ADALIMUMAB

Exempel på hur man kan använda ADALIMUMAB i en mening

• Steroid and/or sulphasalazine treatment are usually the first line of drug based management, although newer drugs along the TNF inhibitor line (such as infliximab and adalimumab) are becoming more widespread in the treatment of inflammatory colonic conditions.
• Even antibodies targeting exactly the same structure are differently prefixed, such as the adalimumab and golimumab, both of which are TNF inhibitors but differ in their chemical structure.
• Inhibition of TNF effects can be achieved with a monoclonal antibody such as infliximab, adalimumab, certolizumab pegol, and golimumab, or with a circulating receptor fusion protein such as etanercept.
• Infliximab as well as other TNF inhibitors like adalimumab, certolizumab, and golimumab are currently the most common biologics used in the treatment of both Crohn's disease and ulcerative colitis.
• Biologics for immunosuppression include adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab, belimumab, and ustekinumab.
• Unlike other TNFi treatments such as adalimumab and certolizumab pegol, there have been no reported cases of drug-induced lupus-like syndrome (DILS).
• Cases of hepatosplenic T-cell lymphoma have been reported in patients treated with the immunosuppressants azathioprine, infliximab, and adalimumab.
• Guselkumab has undergone phase 3 clinical trials comparing it with adalimumab (Humira) and ustekinumab (Stelara).
• The efficacy, safety and tolerability was further investigated in a phase III program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis.
• Its first product, an adalimumab biosimilar, received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023.
• Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis.
• Examples of monoclonal antibodies available or studied as injector pens include adalimumab, secukinumab, and alirocumab.
• Immunosuppressive agents include T-cell inhibitors such as cyclosporine and tacrolimus; antimetabolites such as azathioprine, methotrexate, mycophenolate mofetil, and leflunomide; alkylating agents such as cyclophosphamides and chlorambucil; and biological drugs such as adalimumab.

Förberedelsen av sidan tog: 70,54 ms.